ERBB2 and breast carcinoma: To dissect which specific signalling pathways downstream of HER2 regulate this response, HCC1954 HER2+ breast cancer cells were treated with a panel of inhibitors targeting the main downstream effectors of HER2: PI3K/AKT, MAPK, PLCγ, and JAK-STAT (Figure 1D).